CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating Expenses
Research and development	$ 2,457,051	$ 274,937
Research and development - related party	173,334	450,151
General and administrative	1,272,278	1,281,055
Total Operating Expenses	3,902,663	2,006,143
Loss From Operations	(3,902,663)	(2,006,143)
Other (Expense) Income:
Interest expense	(192,741)	(219,122)
Interest expense - related parties	(2,774)	(49,875)
Amortization of debt discount	(14,970)	(181,299)
Amortization of debt discount - related parties		(28,356)
Change in fair value of derivative liabilities	146,700	485,500
Gain on exchange of accrued liabilities for warrants		73,100
Warrant modification expense	(283,500)
Loss on exchange of notes payable for Series A Convertible Preferred Stock	(262,470)	(191,251)
Loss on extinguishment of debt	(1,504)
Gain on forgiveness of accrued expenses	38,427
Total Other Expense	(572,832)	(111,303)
Net Loss	(4,475,495)	(2,117,446)
Dividend attributable to Series A preferred stockholders	(741,981)	(451,283)
Net Loss Applicable to Common Stockholders	$ (5,217,476)	$ (2,568,729)
Net Loss Per Common Share - Basic and Diluted	$ (0.18)	$ 0.09
Weighted Average Common Shares Outstanding - Basic and Diluted	28,328,575	27,549,867